5 Reasons the Obesity Drug Market Remains Strong

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/a9/af/3b/a9af3be3-4ec4-3ea3-d402-8db74af9b343/mza_2264042129889589570.jpeg/600x600bb.jpg

Thoughts on the Market

Morgan Stanley

1437 episodes

14 hours ago

Short, thoughtful and regular takes on recent events in the markets from a variety of perspectives and voices within Morgan Stanley.

Investing

Business

RSS

All content for Thoughts on the Market is the property of Morgan Stanley and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Short, thoughtful and regular takes on recent events in the markets from a variety of perspectives and voices within Morgan Stanley.

Investing

Business

https://content.production.cdn.art19.com/images/76/41/f5/25/7641f525-1860-44a8-a026-572191dd6825/ad5bdf18b2375d11f3ed84d0afc46cefe256175c8ca37ab5dd0d404d5ff773cc845ca913aafd8c0371680cef060b70198350d6aa6c5936dbcc2263fd69d01d41.jpeg

5 Reasons the Obesity Drug Market Remains Strong

Thoughts on the Market

3 minutes 38 seconds

1 week ago

5 Reasons the Obesity Drug Market Remains Strong

The global market for obesity drugs is expanding. Our U.S. Pharma and Biotech Analyst Terrence Flynn discusses what’s driving the next stage of global growth for GLP-1 medicines.